RNAC Long Call Strategy
RNAC (Cartesian Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd.
RNAC (Cartesian Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $247.4M, a beta of 0.56 versus the broader market, a 52-week range of 5.6-15.57, average daily share volume of 215K, a public-listing history dating back to 2016, approximately 66 full-time employees. These structural characteristics shape how RNAC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.56 indicates RNAC has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on RNAC?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current RNAC snapshot
As of May 15, 2026, spot at $7.37, ATM IV 115.70%, IV rank 21.33%, expected move 33.17%. The long call on RNAC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on RNAC specifically: RNAC IV at 115.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a RNAC long call, with a market-implied 1-standard-deviation move of approximately 33.17% (roughly $2.44 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RNAC expiries trade a higher absolute premium for lower per-day decay. Position sizing on RNAC should anchor to the underlying notional of $7.37 per share and to the trader's directional view on RNAC stock.
RNAC long call setup
The RNAC long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RNAC near $7.37, the first option leg uses a $7.37 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RNAC chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RNAC shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $7.37 | N/A |
RNAC long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
RNAC long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on RNAC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on RNAC
Long calls on RNAC express a bullish thesis with defined risk; traders use them ahead of RNAC catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
RNAC thesis for this long call
The market-implied 1-standard-deviation range for RNAC extends from approximately $4.93 on the downside to $9.81 on the upside. A RNAC long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current RNAC IV rank near 21.33% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RNAC at 115.70%. As a Healthcare name, RNAC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RNAC-specific events.
RNAC long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RNAC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RNAC alongside the broader basket even when RNAC-specific fundamentals are unchanged. Long-premium structures like a long call on RNAC are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RNAC chain quotes before placing a trade.
Frequently asked questions
- What is a long call on RNAC?
- A long call on RNAC is the long call strategy applied to RNAC (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With RNAC stock trading near $7.37, the strikes shown on this page are snapped to the nearest listed RNAC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RNAC long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the RNAC long call priced from the end-of-day chain at a 30-day expiry (ATM IV 115.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RNAC long call?
- The breakeven for the RNAC long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RNAC market-implied 1-standard-deviation expected move is approximately 33.17%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on RNAC?
- Long calls on RNAC express a bullish thesis with defined risk; traders use them ahead of RNAC catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current RNAC implied volatility affect this long call?
- RNAC ATM IV is at 115.70% with IV rank near 21.33%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.